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In vivo tumor cell migration through integrin-dependent pathways is key to the metastatic behavior of malig-
nant cells. Using quantitative in vivo assays and intravital imaging, we assessed the impact of cell migration,
regulated by the integrin-associated tetraspanin CD151, on spontaneous human tumor cell metastasis. We
demonstrate that promoting immobility through a CD151-specific metastasis blocking mAb prevents tumor
cell dissemination by inhibiting intravasation without affecting primary tumor growth, tumor cell arrest, ex-
travasation, or growth at the secondary site. In vivo, this loss of migration is the result of enhanced tumor
cell-matrix interactions, promoted by CD151, which prevent dissociation by individual cells and leads to
a subsequent inhibition of invasion and intravasation at the site of the primary tumor.
INTRODUCTION
While tumor development at the primary site is cause for the on-
set and progression of neoplastic disease, themetastatic coloni-
zation of secondary tissues is clearly the most fatal aspect of
clinical disease (Weiss, 1990; Hanahan andWeinberg, 2000). Tu-
mor cell dissemination involves multiple sequential rate-limiting
steps, including tumor cell mobilization, intravasation, and ex-
travasation, which ultimately result in the colonization of a sec-
ondary site (Bockhorn et al., 2007; Pantel and Brakenhoff,
2004; Bernards and Weinberg, 2002). Throughout the journey
from its original location on route to a distant site, themetastasiz-
ing tumor cell interacts with its changing microenvironment. To-
gether with transmembrane signaling receptors, adhesion com-
plexes on the cell surface convey signals from the instructive
microenvironment and regulate tumor cell behavior. The ability
of the tumor cell to mobilize itself and leave the original tumor
site is one of the prerequisite requirements of tumor cell dissem-
ination (Stracke and Liotta, 1992; Fidler, 2003; Cameron et al.,
2000; Hynes, 2003). Nevertheless, the role of active migration
and invasion in metastasis remains undefined (Bockhorn et al.,
2007).
While alternative, passive methods of dissemination have
been proposed (Weidner, 2002) the identification of the promi-
gratory factors Rho C and Twist as key contributors to the met-
astatic phenotype (Clark et al., 2000; Yang et al., 2004) impli-
cates the need for a functional migration machinery. Cellular
migration is mediated by the adhesion receptors (integrins),
which regulate cellular behavior through cytoplasmic signaling
pathways including Rho GTPases and kinases (Felding-Haber-
mann et al., 2001; Guo and Giancotti, 2004). Adhesion receptor
function is tightly controlled through regulatory pathways that in-
clude integrin-associated transmembrane proteins such as
CD98 (Feral et al., 2005), CD47 (Brown and Frazier, 2001), and
tetraspanins such as CD82 and CD151 (Bienstock and Barrett,
2001; Hemler, 2005).
SIGNIFICANCE
The most lethal aspect of a malignancy, metastatic dissemination, is thought to involve migration machinery that mobilizes
the tumor cell. The aspect of the metastatic cascade that is strictly dependent upon cell motility has, thus far, not been de-
fined clearly. Here, we demonstrate that specific mAb-mediated inhibition of migration, through the integrin-associated tet-
raspanin, CD151, prevents tumor cells from entering the vasculature and subsequent colonization of secondary organs. The
inhibition of migration is due to a dramatic increase in adhesion that prevents cell dissociation and promotes pronounced
immobilization of the tumor cell. The described work illustrates the contribution of tumor cell motility to intravasation and
defines induced enhancement of malignant cell adhesion within the primary tumor as a potential therapeutic approach.Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 221
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Regulation of Tumor Cell Intravasation by CD151The integrin-associated protein CD151 is a member of the tet-
raspanin superfamily characterized by four transmembrane do-
mains and well-conserved cysteine residues in a large extracel-
lular loop (Hasegawa et al., 1998; Sincock et al., 1999; Hemler,
2005). CD151 has been shown to interact directly with the alpha
subunit of several integrins through a small domain (QRD194–196)
within the larger of its two extracellular loops (Kazarov et al.,
2002). While associated with several integrins, the strongest
CD151-integrin interactions are with the laminin-receptor integ-
rins a3b1 and a6b1 (Serru et al., 1999; Lammerding et al., 2003).
Like other tetraspanins, CD151 also interacts with itself, thus
forming small microdomains on the cell surface that incorporate
integrins together with other integrin-associated proteins (Claas
et al., 2001; Charrin et al., 2003), Ig superfamily proteins
(Le Naour et al., 2004), and cadherins (Chattopadhyay et al.,
2003). CD151 has been shown to mediate integrin function by
regulating cytoplasmic signaling. Specifically, CD151 modulates
adhesion-dependent activation of RAS (Sawada et al., 2003),
and integrin-associated CDC42 signaling (Shigeta et al., 2003).
CD151 has been proposed as a cancer marker (Ang et al.,
2004); however, while some components of themolecular mech-
anism of CD151 have been defined in vitro, very little is known
about its in vivo functional role in tumor biology. We have previ-
ously demonstrated that an antibody directed to CD151 can in-
hibit spontaneous metastasis (Testa et al., 1999). However, thus
far it has been unclear how, or at which step of the metastatic
cascade, CD151 contributes to tumor cell dissemination. To ad-
dress these and more encompassing questions, we have devel-
oped quantitative methods of human tumor cell detection based
on PCR amplification of alu sequences, which allow for an ex-
tremely sensitive detection and quantification of each individual
step in the metastatic process (Zijlstra et al., 2002). Furthermore,
to assess motility of tumor cells in vivo, we have extended this
model to now include a useful system for intravital imaging of in-
dividual tumor cell motility.
Using these methodologies, we have demonstrated that the
immobilization of tumor cells with a unique function blocking
anti-CD151 mAb prevents intravasation and subsequent metas-
tasis. The real-time visualization of tumor cell migration in vivo
demonstrates that motility at the secondary as well as the pri-
mary site is substantially inhibited by the anti-CD151 mAb.
Real-time, intravital imaging indicated that the pronounced inhi-
bition of migration was due to an inability of individual tumor cells
to detach at the rear of the cell and depart from their original po-
sitionwithin the tumor stroma. As a consequence of the inhibition
of migration, a dramatic reduction of intravasation at the primary
tumor site was observed which accounted completely for the di-
minished spontaneous metastasis of tumor cells.
RESULTS
Anti-CD151 Antibody, mAb 1A5, Inhibits Spontaneous
Metastasis of Human Tumor Cells In Vivo
We have demonstrated previously that human alu PCR in con-
junction with the chick embryo spontaneous metastasis assay
can be used to quantify metastatic behavior of human tumor
cells in vivo (Zijlstra et al., 2002). By employing these methodol-
ogies in conjunction with a unique metastasis-blocking mono-
clonal antibody (mAb 1A5), the role of the tetraspanin CD151 in222 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.tumor cell dissemination was explored. Animals bearing HEp3
and HT1080 tumors were injected i.v. with control mAb 29-7 or
with purified anti-CD151 monoclonal antibody, mAB 1A5. While
both antibodies persist in the blood for the duration of the
assay and localize to the tumor (Figure S1 available online),
only the anti-CD151 antibody inhibits spontaneous metastasis
(Figure 1A). This inhibition is target specific because control an-
tibodies, which also bind to the surface of HEp3 cells (29-7,
Figure S1), do not interfere with metastasis (Figure 1A). Inhibition
of metastasis is not cell lineage specific since spontaneous dis-
semination of the epidermoid carcinoma HEp3 and the fibrosar-
coma HT1080 are inhibited equally by mAb 1A5. In addition,
large differences in CD151 expression between HEp3 and
HT1080 (inset, Figure 1A) did not affect the ability of mAb 1A5
to inhibit metastasis, nor did the antibody recognize any antigen
in normal chick tissue (Figure S1), further emphasizing the impor-
tance of tumor CD151 in metastasis. Importantly, the level of in-
hibition of HEp3 spontaneous metastasis in the SCID mouse by
mAb 1A5 (>80%) is similar to that observed in the chick, affirming
that the inhibition is not restricted to the chick model (Figure 1B).
In both models, the tumor size is unaffected by antibody treat-
ment (Chick: control IgG, 345.7 mg ± 146.7; anti-CD151, ±
352.25 ± 145.6. Mouse: control IgG, 2.87 g ± 1.29; anti-CD151,
2.86 ± 1.39), indicating that the inhibition of metastasis is inde-
pendent of primary tumor expansion.
Matrix-Mediated Migration of Tumor Cells Is Inhibited
by the mAb 1A5 Independent of the Type
of Matrix Composition
Previous work has suggested that CD151 influences migration
on laminin (Winterwood et al., 2006). To determine if the regula-
tion of migration by CD151 is matrix component specific, the
ability of mAb 1A5 to inhibit the matrix-mediated migration of
HEp3 cells was assessed using a variety of matrixes. Consider-
ing the established association of CD151 with laminin-receptor
integrins (Serru et al., 1999) (a3b1 and a6b1), it is not surprising
that mAb 1A5 inhibited laminin-mediated migration (Figure 2A).
However, mAb 1A5 was also capable of inhibiting migration on
collagen type I (Figure 2B), which is mediated through the a1
and a2 integrin subunits not known to have strong interactions
with CD151. In fact, for each of the tested matrix components
(and thus, their corresponding integrin adhesion receptors),
antibody treatment reduced the level of migration to that on
uncoated filters (Figure 2B). However, mAb 1A5 clearly does
not inhibit matrix-independent migration on uncoated filters.
The inhibition of matrix-mediated migration could be due to
the disruption of adhesion to the matrix components. However,
adhesion to, and spreading on, collagen type I-coated surfaces
in vitro was not disrupted (Figure 2C, upper panels). Further-
more, the formation of paxillin containing focal adhesions was
enhanced (Figure 2C, lower panels), suggesting that antibody
treatment actually enhances matrix interactions rather than dis-
rupting them.
In Vivo Migration Controlled by CD151 Is Critical
for Tumor Cell Motility at the Secondary Site, but Not
for the Extravasation of Arrested Tumor Cells
The observation that the function-blocking mAb 1A5 implements
a broad inhibition of matrix-mediated migration suggests that it
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Regulation of Tumor Cell Intravasation by CD151Figure 1. Treatment with Anti-CD151 Antibody, mAb 1A5, Inhibits Spontaneous Metastasis of Human Tumor Cells In Vivo
(A) Control antibody (29-7) or anti-CD151 monoclonal antibody (1A5) was injected i.v. (100 mg) into HEp3 or HT1080 tumor-bearing chick embryos 1 day after
applying the tumor cells. The level of metastasis to the chick lower CAM (LCAM) was determined by human alu PCR after 7 days as described in the Experimental
Procedures.
(B) To confirm that CD151 also impacts metastasis in another in vivo model, human alu PCR was used to quantify the level of spontaneous metastasis in SCID
mice bearing HEp3 tumors in response to systemic treatment (i.v. injection, 100 mg 32) with mAb 1A5. Values are represented as mean ± SEM.might also inhibit migration within a complex matrix substratum
such as that found in vivo. To perform an analysis of tumor cell
motility in vivo with respect to CD151, we developed the CAM
as a biological platform for the visualization of tumor cell arrest,
extravasation, and migration. (Figure S2).
To assess if mAb 1A5 could interfere with extravasation and
subsequentmigration,GFP-expressing tumor cellswere injected
i.v., and their ability to arrest and disperse within the stroma was
assessed by fluorescentmicroscopy. GFP-expressingHEp3 and
HT1080 cells readily arrested in the CAM vasculature in the pres-
ence and absence of anti-CD151mAb (Figure 3A, Day 1). In sub-
sequent days, the arrested tumor cell population in control ani-
mals expanded and was capable of disseminating widely
throughout the CAM stroma. In contrast, the tumor cell popula-
tion inmAb1A5-treated animals proliferated but apparently failed
to disseminate as they remained tightly clustered, suggesting
these cells cannotmigrate (Figure 3A, Day 3 and 5). This inhibition
is not Fc-dependent but requires the bivalent nature of the IgG
(Figure S5). Both epidermoid carcinoma (HEp3) and fibrosar-
coma (HT1080) demonstrate similar inhibition in motility.
To determine if the failure of tumor cells to disseminate in mAb
1A5-treated animals was due to an inability to extravasate, we
examined the vascular location of the GFP-expressing tumor
cells in the presence and absence of mAb 1A5. At 24 hr postin-
jection, all of the cells in animals treated either with control anti-
body or with mAb 1A5 had extravasated (N = 300, Figure 3B, left
panels, Z projection). At 5 days postinjection, the extravasated
cells had proliferated in both control and mAb 1A5-treated ani-
mals. However, in control animals, these cells had migrated
throughout the stroma, while in mAb 1A5-treated animals, the
extravasated cells proliferated but failed to disseminate and,
thus, formed clusters or compact colonies immediately outside
the vasculature (Figure 3B, right panels, z-projection). These ob-
servations indicate that the inhibition of migration by anti-CD151
mAb 1A5 appears not to be critical for vascular extravasation but
prevents active migration of the tumor cells within the stroma
after departure from the vasculature.The Tumor Cell Immobility Mediated by CD151 upon
Antibody Ligation Does Not Reduce the Arrest
and Growth of Tumor Cells In Vivo
HEp3 cells were injected i.v. in the presence of control mAb or
anti-CD151 mAb, and their arrest in both the CAM and lung at
24 hr and the subsequent proliferation of arrested cells 4 days
postinjection were determined quantitatively by Alu PCR. A com-
parable number of arrested cells (1000 cells in the LCAM and
200 cells in the lung) were detected in treated and control ani-
mals (Figure 3C, Day 1). Furthermore, a 5-fold increase in cell
number occurs in the LCAM and a 2-fold increase in the lung
for both mAb 1A5 and control mAb-treated animals (Figure 3C,
Day 4). The tissue-specific lag in tumor cell proliferation seen
in the lung was observed previously (Zijlstra et al., 2002). These
data confirm that the inhibition of motility by mAb 1A5 does not
affect tumor cell arrest or growth in vivo.
Inhibition of Motility by mAb 1A5 Eliminates
the Invasive Edge of the Primary Tumor
Although the loss of motility mediated by anti-CD151 prevents
migration at the secondary site, it does not limit metastatic colo-
nization by tumor cells injected intravenously (Figure 3). This in-
ability to influence postintravasation metastatic events indicates
that the inhibition ofmigration plays a critical role in the departure
from the primary site. To monitor the migratory behavior of cells
within the primary tumor, we developed a distinct intravital imag-
ing system (see the Experimental Procedures). GFP-expressing
HEp3 cells (5 3 104) were implanted into the CAM of ex ovo
embryos and allowed to form a primary tumor. The animals
were treated with a control mAb or mAb 1A5 at 24 hr postimplan-
tation, and the tumors were imaged 7 days later. The hallmark of
aggressive metastatic tumors is an irregular invasive front seen
at the tumor-stromal interface (Friedl and Wolf, 2003; Hood
and Cheresh, 2002; Geho et al., 2005; Liotta and Kohn, 2001).
This invasive front is clearly visible in control HEp3 and HT1080
tumors (Figure 4) where tumor cells have invaded the stroma sur-
rounding the primary tumor, thereby generating an irregular
Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 223
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Regulation of Tumor Cell Intravasation by CD151Figure 2. Anti-CD151 Metastasis-Blocking
mAb 1A5 Mediates Inhibition of Migration
Independent of the Underlying Matrix
Transwell migration of HEp3 cells in response to
an underlying matrix was assessed in the pres-
ence of mAb 1A5 or an unspecific control mAb.
Haptotactic migration of HEp3 in response to lam-
inin (LN, [A]) was assessed during a 16 hr incuba-
tion and compared to migration on control (un-
coated) filters. (B) Comparative summary of 1A5
inhibition of matrix mediated migration by HEp3
on LN, Fibronectin (FN), Vitronectin (VN), Col I,
and Collagen type IV (Col IV). Values in (A) and
(B) are represented as mean ± SEM (C) Adhesion
of HEp3 cells to collagen type I coated coverslips
in the presence of control mAb or mAb 1A5 was vi-
sualized using phase contrast microscopy (upper
panels). Immunofluorescent staining for Paxillin vi-
sualizes the formation of focal adhesion com-
plexes on a collagen type I substrata in the pres-
ence of a control mAb or mAb 1A5 (lower
panels). A 2- to 3-fold enhancement of paxillin
containing focal adhesion complexes was ob-
served in the presence of mAb 1A5. Scale bars,
10 mm.border. Highmagnification (1003) imaging demonstrates that in-
dividual cells have migrated into the stromal tissue and appear
particularly abundant along the stromal vasculature. It is not sur-
prising that tumor cells indeed migrate rapidly along the vascu-
lature (Figure S4 and Movie S8), a phenomenon also reported
in a mouse tumor model (Wyckoff et al., 2000). In contrast,
mAb 1A5-treated tumors exhibit a very defined border with little
or no invasion of the surrounding stroma nor migration along the
vasculature for both HEp3 and HT1080 tumors (Figure 4, lower
panels).
Inhibition of Individual Tumor Cell Migration by mAb
1A5 Prevents Invasion of the Adjacent Stroma
To determine if CD151-mediated control of migration was re-
sponsible for intratumoral cell motility in vivo, changes in veloc-
ity, distance, and directionality of tumor cell motility in HEp3 tu-
mors in response to mAb 1A5 were assessed using intravital
microscopy. HEp3 tumor cells were implanted in the CAM, and
the motility of individual tumor cells was imaged over a 12.25
hr period in the presence and absence of mAb 1A5 (Figures 5A
and 5B). A representative population of motile cells, whose
path could be traced during the entire time period, was analyzed
by tracking the centroid of individually selected cells. For each
individual cell, the total distancemigrated and the productive mi-
gration (distance from origin) was calculated (Figure 5C). In addi-
tion, the velocity, persistent forward motion (persistence), and
changes in directionality (angle change) were determined for
each cell.
Individual HEp3 cells exhibit a high level of motility (22 mm/hr
for a total distance of 288 mm;Movie S1; Figure 5D). This average
velocity compares favorably with the high speeds of 20–40 mm/hr
recorded in two- and three-dimensional culture in vitro for cancer
cells of epithelial origin (Soon et al., 2005; Harms et al., 2005).
More important, HEp3 cells exhibit a persistence of 4.39 mm,
which facilitates a productive migration of 150 mm in untreated
animals (Figures 5C and 5D). Tracking of individual cells clearly
demonstrates the ability of HEp3 cells to rapidly penetrate the
stroma surrounding the primary tumor (Figure 5A, control tracks
3 and 8). In contrast, the inhibition ofmotility is readily apparent in
mAb 1A5-treated animals (Figure 5B and Movie S2). Tumor cells
in antibody-treated animals exhibit an approximate 4-fold inhibi-
tion of migration velocity (5.9 mm/hr), which, together with a 3.6-
fold inhibition of persistence (1.21 mm), results in a 6.6-fold re-
duction in productive motility (23 mm, Figures 5C and 5D). The
substantial reduction in motility upon treatment with mAb 1A5
is apparent when the traces of individual tumor cells are plotted
on a singular origin in a Wind-Rose plot (Figures 5A and 5B, right
panels).
In mAb 1A5-treated animals, the tumor cells clearly exhibit
some residual movement in the presence of mAb 1A5, and their
ability to change direction is unaffected (Figure 5D). Pseudopo-
dial extensions and small forward and backward movements
are readily observed within the tumor (Figure 5B, tracks 1 and
2; Movie S2). However, considering an approximate body length
of 20 mm, on average, the mAb 1A5-treated tumor cells fail to
travel more than one body length from their original position,
while in control animals, the average tumor cell travels 5–7
body lengths away from their original start position (Figures 5A,
5B, and 5D).
Inhibition of Motility by Anti-CD151 Is Mediated
Mechanistically by the Inability of Tumor Cells
to Detach at the Rear of the Cell Body
The migratory behavior of HEp3 cells in vivo was analyzed in
greater detail by capturing enhanced images of individualmigrat-
ing cells in control and mAb 1A5-treated animals (Figure 6). In
control tumors, migrating cells can be seen to invade the sur-
rounding stroma as the leading edge of the cell penetrates the
mesenchymal tissue (Figure 6A, arrow). When the cell body
moves forward in the direction of the invading pseudopodia,224 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.
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Regulation of Tumor Cell Intravasation by CD151the trailing end of the cell (arrowhead) detaches and rapidly con-
tracts toward the cell body (Figure 6A, cells 1 and 2; Movies S3
and S4). These motile control cells were compared to the most
Figure 3. In Vivo, Intrastromal Tumor Cell
Migration, but Not the Arrest, Extravasation,
or Growth at the Secondary Site of Metasta-
sis Is Affected by Anti-CD151 mAb 1A5
(A) The ability of anti-CD151 to impact in vivo mo-
bility was determined by visualizing the intrastro-
mal mobility of GFP-expressing HEp3 (upper
panels) and HT1080 (lower panels) cells in the
CAM when coinjected with 100 mg anti-CD151 or
a control IgG. Blood-containing vessels are seen
in black while GFP-expressing cells are bright
green against the dull green glow of the eggshell.
Each image is representative of twelve animals im-
aged in four separate experiments.
(B) Alterations in the ability of tumor cells to arrest,
extravasate, and colonize were assessed by con-
focal imaging of GFP-expressing HEp3 (green)
cells in CAM with Lectin-labeled vasculature
(red). Tumor cells coinjected with anti-CD151 or
control IgG were imaged at 24 hr and 5 days post-
injection. Merged topical view and vertical projec-
tion of a resliced Z-stack taken from a selected
area (white box) illustrate the location of tumor
cells relative to the vasculature. Tumor cells that
remain inside the vasculature would be seen as
yellow while extravasated cells are only seen in
green (for further detail, see Figure S2). Included
images are representative of twelve animals from
four separate experiments.
(C) Alu PCR analysis of experimental metastasis
was used to quantify the affect of inhibited tumor
cell migration on arrest (Day 1) and growth (Day
4) in the lung and the lower CAM (LCAM). HEp3 tu-
mor cells (50,000) were injected into the allantoic
vein of a 10-day-old chick embryo. Tissue was
harvested 3 hr after injection to quantify the num-
ber of arrested tumor cells or at 4 days after injec-
tion to assess the growth of the arrested cells.
Similar results were obtained in 3 experiments.
n = 5. Values in (C) are represented as mean ±
SEM. Scale bars: (A), 200 mm; (B), 20 mm.
motile of the tumor cells in the mAb 1A5-
treated animals (such as Figure 5B, track
5, represented as cell 1 in Figure 6B).
The enlarged frames in Figure 6B illustrate
that the cells in the mAB 1A5-treated ani-
mals invade the stroma and appear to be
capable of forward movement (see arrow,
Figure 6B, cells 1 and 2). However, even
though the centroid travels approximately
100 mm from the original position, the rear
of the cell fails to follow the movement of
the cell body and remains attached close
to the original location (see arrowhead,
Figure 6B, cells 1 and 2; Movies S5 and
S6). A quantification of the migratory be-
havior of individual cells (n = 250) at the tu-
mor-stroma interface demonstrated that
83.3% of these boundary cells in control tumors were motile
(move more than one body length, >20 mm), and only 1.7% of
these motile cells failed to detach at the rear of the cell duringCancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 225
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Regulation of Tumor Cell Intravasation by CD151Figure 4. The Inhibition of Migration Prevents Tumor Cell Inva-
sion at the Tumor-Stroma Interface
GFP-expressing HEp3 and HT1080 CAM tumors were imaged intravitally
using a newly developed intravital imaging system (see the Experimental
Procedures) to visualize the invasive behavior of metastatic tumor cells.
Chick embryos were injected i.v. with 100 mg of mAb 1A5 or control
mAb 24 hr after CAM implantation of GFP-expressing HEp3 cells. Im-
ages were taken 7 days after antibody treatment. The included images
are representative of 10 individual tumors generated in two separate
experiments with five animals each. Scale bars: (403), 800 mm; (1003),
100 mm.the time of observation (12.5 hr). In contrast, in mAb 1A5-treated
tumors, 24% of these boundary cells exhibited such motility but
88% of these ‘‘motile’’ cells failed to detach at the rear of the cell.
As a consequence, 81.4% of control cells exhibited productive
motility compared to less than 3%of the cells inmAb1A5-treated
tumor.
Within a growing tumor, the inability of a proliferating cell to
productively depart from its original position should result in
a small compact colony of daughter cells. This was indeed true
in primary tumors harvested from chick embryos treated with
control mAb or mAb 1A5 (Figure S3). In addition, it was shown
that in mAb 1A5-treated embryos, daughter cells fail to depart
the location of the original parental cell during secondary site col-
onization (Figure 3B, 3C).
The failure to detach induced by the anti-CD151 mAb is also
observed in vitro (Figures 6C and 6D). HEp3 cells treated with
a control mAb clearly migrate and exhibit distinct detachment
at the rear of the cell. In contrast, treatment with mAb 1A5 pre-
vents detachment at the rear of the cells (white arrows), causing
the cell to move back and forth in the same location without
achieving productive movement. By quantifying detachment at
the rear for individual tumor cells (Figure 6D, n = 30), the failure
to detach and migrate productively is apparent (Figure 6D). In
a three-dimensional collagen matrix, HEp3 cells which can in-
vade the collagen matrix in the presence of a control mAb (Fig-
ure 6E, arrow) are completely immobilized in the presence of
mAb 1A5 and form compact colonies (Figure 6E, right panel)
as was also seen in the CAM in vivo (Figure 3B).
The Loss of CD151 Does Not Significantly Impact In Vivo
Motility while Anti-CD151 mAb Treatment Mediates
Immobility Only in the Presence of Human CD151
Recent reports of CD151 knockout mice have indicated that the
genetic loss of CD151 does not result in dramatic developmental
deficiencies (Wright et al., 2004; Sachs et al., 2006; Takeda et al.,
2007), suggesting that migration is not critically impaired in these
mice. To further explore the immobility mediated by CD151, we
compared the in vivo migration of mouse embryonic fibroblasts
(MEF), which lacked CD151 expression (MEFCD151/) with wild-
type MEF (MEF-WT) and with MEFCD151/, which were recon-
stituted with human CD151 (MEFCD151/hCD151). As seen
in Figures 7E, 7G, and 7I, MEF-WT, MEFCD151/, and226 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.MEFCD151/hCD151 all migrate into the stroma as individual
cells, away from the point of CAM implantation (white arrows,
Figures 7E–7J). These observations indicate that the mere ab-
sence of CD151 does not significantly impair the in vivo mobility
of a migrating cell. Similarly, the downregulation of CD151 ex-
pression in HT1080 cells by shRNA (Figure 7K) did not limit tumor
migration in vivo (compare Figures 7A and 7C) nor did it inhibit
metastasis significantly (Figure 7L). In contrast to the loss of
CD151, treatment of HT1080 cells and MEFCD151/hCD151
with anti-CD151 mAb 1A5 blocks invasion of the stroma (Figures
7B and 7J), and the cells remain tightly clustered at the CAM im-
plantation site. However, cells that lack human CD151 (MEF-WT)
or are substantially reduced in CD151 expression (HT1080
shRNACD151, MEFCD151/) are unaffected by the antibody (Fig-
ures 7D, 7F, and 7H), indicating further that the anti-CD151 mAB
is specific and is not targeting other molecules, which might
result in off-target inhibition of motility. In addition to these illus-
trative in vivo results, HT1080 cell migration assays carried out
in vitro on collagen coated surfaces also demonstrated that
mAb 1A5 inhibits motility only when the CD151 antigen is present
at normal levels on the cell surface (Figure S6). These obser-
vations demonstrate that cell surface CD151, upon antibody
binding, induces pronounced immobility of individual cells.
Anti-CD151-Mediated Inhibition of In Vivo Motility
Results in Complete Inhibition of Tumor
Cell Intravasation
Since the anti-CD151-mediated inhibition of migration is a con-
sequence of the inability of mAb 1A5-treated cells to detach at
the rear of the cell, these tumor cells should not be able to es-
cape from the primary tumor and enter the vasculature (intrava-
sate). The arrival of intravasated human tumor cells in the lower
CAM of tumor-bearing chick embryos is readily quantified (Fig-
ure 8) using the human alu PCR-based assay (Zijlstra et al.,
2002). Intravasating tumor cells are first observed in the lower
CAM on day 3 and continue to arrive every day thereafter. The
intravasated tumor cells which arrive in the CAM proliferate in
the ensuing days with an approximate doubling time of 21–24 hr.
In order to ascertain the number of intravasating cells arriving
in the lower CAM within a single day, we determine the increase
in the tumor cell population between day 5 and 6 and compare
that with the number predicted solely on the basis of a doubling
Cancer Cell
Regulation of Tumor Cell Intravasation by CD151Figure 5. Tumor Cell Motility Is Inhibited at the Tumor-Stroma Interface in mAb 1A5-Treated Animals
GFP-expressing HEp3 tumor cells were imaged intravitally for 12.25 hr in order to visualize, record, and quantify the in vivomotility of individual tumor cell (see the
Experimental Procedures). Antibody treatment was given i.v. 24 hr after tumor cell implantation and imaging was initiated 48 hr later. Images were captured every
15min. Themotility of tumor cells in a tumor developing on a control animal (A) and amAb 1A5-treated animal (B) is represented by comparing the first frame (0.00
hr) and the last frame (12.25 hr) of a 12.25 hr movie (seeMovie S1 [control] andMovie S2 [mAb 1A5]). Themigration of individual cells is visualized as an overlay of
dots and lines in each frame (left panels). The tracks of ten representative cells are plotted in Wind-rose plots (right panels) with the initial position of each track
superimposed at 0,0 to provide a relative overview of the migration tracks with a single point of origin. The temporal increase in the productive motility of 4 rep-
resentative tracks from control and treated tumors are plotted in (C). The most motile cell in the mAb 1A5 treated tumor (5) is still far less motile than the average
control cells. (D) The motility parameters were determined quantitatively for cells in a tumor from animals treated with either control mAb or mAb 1A5. Motility
parameters were determined as an average of 30 cells/tumor with 48 measurements/cell. p values were calculated using Student’s t test. A highly significant
reduction in forward motility, but no change in the ability to alter direction (turn angle), is apparent. Values are presented as mean ± SEM and representative
of 3 distinct experiments. Scale bars in (A) and (B), 100 mm.of those cells detected on day 5. The number of intravasated
cells is the difference between the actual number cells present
in the tissue and the number of cells expected due to cell dou-
bling. In control animals, 6050 cells are present in the CAM on
day 5 which should grow to 12,000 cells by day 6 on the basis
of their doubling time (dashed line in Figure 8A). However,
29,000 cells are actually measured on day 6, yielding a calcu-
lated value of 17,000 newly arriving cells between day 5 and 6
(area above dashed line, Figure 8A). In contrast, there was no de-
tectable intravasation over the same time period in mAb 1A5-
treated animals as the approximately 1000 cells present in the
lower CAM on day 5 failed to increase in numbers beyond a dou-
bling (Figure 8A). Tumor growth in all of these experiments (Fig-
ures 8A and 8B) was not significantly different between control
IgG and anti-CD151 treated animals and increased approxi-
mately 50 mg from D5 to D6.
We proposed that the inhibition of motility on any given day
would bring about an abrupt inhibition of intravasation. Indeed,
when chick embryos bearing HEp3 tumors were injected with
mAb 1A5 on day 5, the tumor cell population detected in the
CAM on day 5 (2,150) only expands to 4,470 cells by day 6 in
close accordance to the cell doubling rate, and no newly intrava-
sating cells are detected (area above the dotted line, Figure 8B).
In contrast, control antibody-treated animals yield 11,500 cells
on day 6, of which only 4,300 could be predicted from prolifera-
tion, thereby indicating a rate of intravasation of 7,200/24 hr.
These quantitative tumor cell measurements are consistent
with the in vivo motility and morphological observations and
demonstrate that CD151-mediated inhibition of motility subse-
quently prevents intravasation and thereby ultimately inhibits tu-
mor cell dissemination.
DISCUSSION
The Regulation of Metastasis through Individual
Tumor Cell Migration
This work identifies the role of tumor cell migration in metastasis
as regulated through the tetraspanin CD151. Using highly sensi-
tive detection of human tumor cells by PCR, along with intravital
visualization of tumor cell migration, we determined that CD151
can control deadhesion at the rear of the cell, which thereby pro-
motes immobility of tumor cells and, as a consequence, the suc-
cessful dissemination of tumor cells from the primary tumor.
Contrary to the ablation of CD151 expression, the ligation of
CD151 with its cognate mAb 1A5 results in immobilization of
CD151-expressing tumor cells. These observations demon-
strate thatmetastasis requiresmigration as an active component
of dissemination and intravasation.
The immobilization mediated by CD151 upon antibody ligation
prevents invasion and dissemination at a number of points in the
metastatic cascade, including migration within the primary tu-
mor and at the secondary location. However, with regards to
the full metastatic ability of human tumor cells, individual cell mi-
gration was critical only in the departure from the primary tumorCancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 227
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Regulation of Tumor Cell Intravasation by CD151Figure 6. Anti-CD151 Mediated Inhibition of Migration Coincides with Incomplete Detachment at the Rear of the Cells
Selected fields from real-time movies were captured, enhanced, and processed to reveal the details of migration in the three-dimensional stroma of tumor-bear-
ing animals treated with control mAb (A) or anti-CD151 mAb 1A5 (B). Also, see Movies S3, S4, S5, and S6. A white arrow indicates the leading edge of the mi-
grating cell and a white arrowhead indicates the trailing end of the same cell. The scale bar is 20 mm and the time is marked on each frame. Note that, due to the
differential in migration rates, the time line for the control cells is 0.5 hr/frame while the 1A5-treated cells are shown at 1.25 hr/frame. Anti-CD151-induced loss of
detachment was confirmed in vitro by visualization (C) and quantitation (D) of HEp3 cell migration on a collagen monolayer (2003, large arrow indicates start
position of the rear and small arrow indicates the protrusive edge. Also see Movie S9). The impact on invasion was assessed in vitro using HEp3 cultivated in
3-dimensional collagen (E) where the loss of invasion (white arrow, left panel) and the formation of compact circular colonies was evident (right panel). Scale
bars: (A), (B), and (C), 20mm; (E), 10 mm.228 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.
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Regulation of Tumor Cell Intravasation by CD151Figure 7. Anti-CD151 mAb Ligation Pro-
motes Immobility while the Loss of CD151
Fails to Impact In Vivo Motility
The necessity of CD151 expression for in vivo mo-
tility of tumor cells and MEF was assessed by im-
planting fluorescently labeled cells with reduced
or ablated CD151 expression into the CAM and
determining their ability to depart the implantation
site. The ability of HT1080 cells stably transduced
with an expression vector containing GFP
(HT1080) or CD151-specific shRNA (HT1080
shRNACD151) to migrate out as individual cells
was assessed in the presence of control antibody
(A) and (C) or anti-CD151 mAb 1A5 (B) and (D) at 4
days after tumor cell implantation. The white dot-
ted line demarks the border of the primary tumor
while arrows indicate the stromal invasion of tumor
cells. Likewise, the inability of anti-CD151 mAb
1A5 to prevent individual wild-type MEF ([E] and
[F], MEF wt) and CD151 knockout MEF ([G] and
[H], MEFCD151/) from mobilizing, departing the
implantation site, and entering the stroma was il-
lustrated by fluorescent microscopy 4 days after implantation. Similarly, the mobility of MEFCD151/ reconstituted with hCD151 ([I], MEFCD151/ hCD151)
was assessed in the CAM. To illustrate the ability of anti-CD151 to actively promote immobility, the ability of MEFCD151/hCD151 to disseminate from the im-
plantation site was determined in the presence of mAb 1A5 (J). Each image is representative of 3 individual experiments with 3 animals each. A white arrow (E–J)
indicates the injection site. Downregulation of endogenous CD151 in HT1080 shRNACD151 is confirmed by western blotting of whole-cell lysates with anti-CD151
antibody (K). The impact of ablated CD151 expression on metastasis and the specificity of anti-CD151 treatment was further investigated by quantifying metas-
tasis of HT1080 GFP or shRNACD151 in the presence or absence of anti-CD151 mAb 1A5 (L). Values represent the mean ± SEM where n = 8. Scale bars, 200 mm.and entry into the vasculature (intravasation). In contrast, arrest,
extravasation, and proliferation at the secondary location ap-
peared unaffected by the lack of productive motility. Tumor cells
introduced directly into the circulation in the presence of anti-
CD151 during experimental metastasis were able to arrest, ex-
travasate, and proliferate within the surrounding stroma.
The Impact of Tumor Cell Immobilization by Anti-CD151
on the Progression through Individual Stages
of Metastasis
It is of interest that extravasation, a process that involves active
motility by the tumor cells (Luzzi et al., 1998; Chambers et al.,
1992) (Movie S7), is not prevented by the inhibition of CD151-
mediated migration. However, since extravasation requires ar-
rested tumor cells to pass through a thin layer of endothelial cells
and basement membrane without dissociating from any previ-
ously formed matrix contacts, this process can be achieved in
a single body length. Individual cells in mAb 1A5-treated animals
exhibit the ability to extend one body length (15–20 mm) even
though they fail to dissociate from their original location (Fig-
ure 6). This distance would be sufficient to pass through the vas-
cular wall and enter the surrounding stroma. Since in vivo growth
is not affected by mAb treatment, no diminishment of secondary
site colonization occurs during experimental metastasis.
In contrast to experimental metastasis, spontaneousmetasta-
sis is inhibited >80%, thereby emphasizing the importance of
CD151 in the departure of tumor cells from the primary tumor.
Cells within the primary tumor exhibit a continuousmobility, illus-
trating that no tumor cell is ‘‘static’’ or entirely immotile. While
much of the movement appears random, in fact a portion of
the cells exhibit a persistent forwardmovement that facilitates in-
vasion of the stroma (Figure 5A). This forward mobility is not al-
ways outwards but is also directed into the tumor mass (track7 in Figure 5A), indicating that the migratory clues are not a sim-
ple, unidirectional chemotactic stimulus from the stroma. When
plotting the productive migration of tumor cells, we observe
that many migratory cells move forward in bursts of activity pre-
ceded or followed by a period of nonproductive movement. This
migration appears to be guided at least in part by the vasculature
(Figure S4 and Movie S8).
The 3- to 4-fold reduction in overall (total) tumor cell motility
would not account for the near absence of invasion and the
>80% reduction in spontaneous metastasis. However, a quanti-
tative analysis of the motion parameters demonstrates that both
the velocity and the persistence of movement are reduced
3- to 4-fold. Together, they are responsible for a 6- to 7-fold re-
duction in productive movement away from the point of origin
(Figure 5D). Furthermore, because the mAb 1A5-treated tumor
cell fails to depart its original position, even as it possesses
some minimal movement, no significant productive departure
from the primary tumor can be achieved, and thus, little or no
metastasis can occur.
The inhibition of migration, it should be emphasized, does not
result in the disruption of adhesive interactions but rather in the
prevention of deadhesion. Our direct in vivo and in vitro observa-
tions of this behavior are corroborated by the quantitative mea-
surements of migration. A disruption of adhesive capacity would
have resulted in a complete loss of any movement, thus yielding
a ‘‘0’’ value for all migration parameters. Conversely, loss of che-
motactic or directional movement would lead to a reduction in
persistence and a subsequent reduction in productive motility
without changes in velocity or even total migration. In contrast,
the joint decrease in velocity and persistence observed in mAb
1A5-treated animals corresponds with the reduced ability to
deadhere. Rear detachment of migrating cells has previously
been suggested to be the rate-limiting step in 2D migration inCancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 229
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Regulation of Tumor Cell Intravasation by CD151Figure 8. Function-Blocking Anti-CD151
Antibody, mAb 1A5, Inhibits Tumor Cell
Intravasation
(A) Intravasation in animals treated i.v. on day 1
with mAb 1A5 or control mAb (mAb 29-7) as deter-
mined by alu PCR. The dashed line indicates the
number of cells expected on day 6 based upon
the growth (24 hr doubling time) of cells detected
on day 5. The bar volume above the dashed line
represent the number of intravasated cells. Similar
results were obtained in 3 experiments. n = 6.
(B) To assess the immediate impact of mAb 1A5-
arrested intravasation on metastasis, HEp3 tu-
mor-bearing animals were injected 24 hr prior to
harvesting the LCAM. The number of intravastated
tumor cells in CAM tissue harvested on day 6 after
a mAb treatment on day 5 was compared with the
number of cells found in day 6CAM fromuntreated animals. Values are represented asmean± SEM. *p% 0.01, **p% 0.001. Tumor sizes in (A): control: D5, 143.5 ±
61; D6, 216 ± 100. mAb 1A5: D5 167 ± 72, D6 200 ± 85. Tumor sizes in (B): D5, 115 ± 40; control: D6, 200 ± 66; mAb 1A5: D6, 191 ± 71.vitro (Gallant et al., 2005; Palecek et al., 1998).We present an ob-
servation that specifically demonstrates that an integrin-associ-
ated tetraspanin can control the cell’s adhesive machinery such
that it fails to disengage and, thus, prevents productivemotility of
a tumor cell in vivo. That this can occur within a complex ECM
such as the tumor stroma with multiple adhesion ligands, indi-
cates the importance of deadhesion in tumor cell motility.
While the exact mechanism by which CD151 controls migra-
tion is currently unknown, the direct interaction of CD151 with
the laminin-receptor integrins (a3b1 and a6b1) suggests that
the tetraspanin might regulate migration through direct control
of integrin function. Indeed the expression of CD151 correlates
positively with migration on laminin (Winterwood et al., 2006;
Sterk et al., 2002) and CD151 has been shown to potentiate
ligand binding activity of a3b1 and a6b1 (Nishiuchi et al., 2005;
Lammerding et al., 2003). Most importantly, CD151 can facilitate
adhesion strengthening (Nishiuchi et al., 2005; Lammerding
et al., 2003), a process that can reduce migration by inhibiting
detachment of the cell (DiMilla et al., 1993; Palecek et al.,
1997). Our in vitro and in vivo observations suggest that
CD151 can promote immobility on a variety of matrixes in addi-
tion to laminin. Furthermore, themere expression of CD151 does
not appear to be sufficient for regulating migration in vivo (Fig-
ure 7), an observation which is supported by the normal embry-
onic development of three independently generated CD151
knockout mice (Wright et al., 2004; Sachs et al., 2006; Takeda
et al., 2007). Human patients with CD151 deficiencies suffer prin-
cipally from regional skin blistering, sensorineural deafness, and
kidney failure. The latter is also found in knockout mice. How-
ever, neither human nor mouse fails to form organs or heal skin
wounds in the absence of CD151 suggesting that, at a cellular
level, cells which lack CD151 retain a functional migration ma-
chinery. The migration of MEFCD151/ in CAM stroma (Figure 7)
confirms this hypothesis. Conversely, the near complete failure
of CD151-positive human tumor cells and MEFCD151/-ex-
pressing human CD151 to detach in response to anti-CD151
mAb demonstrates that antibody-bound cell surface CD151
can promote tumor cell immobility through a dominant-negative
effect on migration. This action is likely to be mediated through
an associated effector molecule because tetraspanins act pri-
marily as scaffolding proteins in the membrane.230 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.While direct interaction between integrins and CD151 is evi-
dent, several nonintegrin membrane proteins, which can regu-
late motility, are also associated with tetraspanin-enriched
microdomains (Claas et al., 2001; Hemler, 2005). These mem-
brane proteins include growth factor receptors (Klosek et al.,
2005), Ig superfamily proteins and cell adhesion molecules (Le
Naour et al., 2006), and E-Cadherin (Chattopadhyay et al.,
2003), each of which is capable of impacting migration indirectly.
The continued ability of CD151-negative cells to migrate in vitro
and in vivo indicates that CD151 is neither sufficient nor neces-
sary for migration. In contrast, the inhibition of migration in
CD151 expressing tumor cells with the anti-CD151 mAb 1A5 in-
dicates that the tetraspanin can promote immobility. This immo-
bilization does not appear to depend on steric hindrance
because monomeric Fab fragment of 1A5 binds to CD151 on
tumor cells but does not promote immobility (Figure S5). In the
absence of catalytic domains in CD151, it is likely that CD151 re-
cruits elements that promote immobility or sequesters elements
needed for deadhesion upon ligation with the cognate antibody.
The identification of the partner(s) that associate with CD151 and
mediate control over cellular (de)adhesion should reveal the mo-
lecular mechanism responsible for controlling deadhesion. Such
identification studies are now ongoing.
Preventing Metastatic Dissemination through
the Inhibition of Migration
The microenvironment to which a metastasizing tumor cell is ex-
posed en route to a secondary site is both an architectural aswell
as a signaling framework that is continually instructive with re-
gards to cellular behavior (Bissell and Labarge, 2005). The pri-
mary approach to intervening with the invasive nature of cancer
has been focused on the identification and disruption of extracel-
lular signals that promote migration (Wyckoff et al., 2004; Clark
et al., 2000), the disruption of adhesive properties (Murphy-Ull-
rich, 2001; Czekay et al., 2003), or the disruption ofmigrationme-
diated signaling downstream of the cell surface sensors (Guo
and Giancotti, 2004). Since adhesive interactions with these
highly instructive surroundings are in large part responsible for
migration, it may seem intuitive that disruption of such adhesions
would prevent tumor cell dissemination. However, our data pres-
ent a case study in which the contrary, the inhibition of
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preventing metastasis.
The disruption of a single adhesive function through blocking
antibodies or peptides directed toward the ligand or its receptor
(integrin) can readily disrupt in vitro adhesion and migration
(Ruoslahti, 1996) or alter the survival (Stupack et al., 2006) and
morphology (Kenny and Bissell, 2003) of tumor cells within the
matrix. However, within the complexity of the in vivo stroma, it
is difficult to disrupt the multitude of adhesive interactions effec-
tively. In fact, disabling or blocking a single proteolytic or adhe-
sive event often causes a tumor cell to alter their mechanism of
migration without the loss of productive motility (Friedl and Wolf,
2003). In contrast, a single interfering step that prevents dissoci-
ation can immobilize the target cell without having to out-com-
pete newly available adhesion sites, continuously renewing che-
motactic stimuli or matrix modifying enzymatic activities. This is
apparent in our ability to promote immobility onmultiple matrixes
to which the tumor cells adhere (Figure 2). The immobilization
that occurs does not prevent localized protrusion and forward
movement of the cells. In contrast, immobilized cells can be
seen protruding into the immediate surroundings and adhering
to the newly invaded space. However, as the rear of the cell fails
to dissociate, the cell halts upon extending one body length and
remains immotile or returns to its original location (Figure 6). Ul-
timately, the consequence of this inability to dissociate blocks
the invasive behavior of tumor cells and prevents intravasation
and, thereby, the metastasis of primary tumor cells.
The role of migration as an active contributor to metastasis is
a central question at the forefront of metastasis research (Bock-
horn et al., 2007). The immobility mediated by CD151 upon anti-
body ligation is in vivo proof of principle that migration is an ac-
tive mechanism that contributes to metastasis. Furthermore, it is
to our knowledge the first direct evidence demonstrating that
regulation of deadhesion can function as a powerful antimetasta-
sis target. Improving the stabilizing interactions of tumor cells
with the microenvironment has already proven successful in re-
verting the malignant phenotype independent of its genetic in-
structions (Weaver et al., 1997). Negative regulators ofmigration,
which enhance adhesion of tumor cells to their surroundings,
could be highly effective in preventing the invasive behavior of
tumors as well as inhibiting metastasis. The CD151-mediated in-
hibition of migration clearly demonstrates the role of migration in
tumor cell departure from the primary tumor and the role of
CD151 and cell deadhesion in tumor cell motility, intravasation,
and subsequent metastasis.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents
The epidermoid carcinoma cells (HEp3) and fibrosarcoma cells (HT1080) were
maintained as described previously (Zijlstra et al., 2002). CD151/ mouse
embryonic fibroblasts (MEFCD151/) were kindly provided by the laboratory
of Dr. Sonnenberg (Netherlands Cancer Institute). Wild-type MEF and
MEFCD151/ were immortalized using pBRSV (ATCC) encoding SV40 Large
T antige, and human CD151-GFP expression was reconstituted in
MEFCD151/ (MEFCD151/hCD151) by transduction with PLXN containing
CD151-GFP. Transduction with shRNA containing the target sequence
GCCTCAAGTACCTGCTGTTTAC was used to downregulate CD151 expres-
sion in HT1080 cells (HT1080shRNACD151). Positive and negative cell sorting
was used to collect MEFCD151/hCD151 and HT1080shRNACD151, respec-
tively. The anti-CD151 monoclonal antibody 1A5 (mAb 1A5) and control anti-bodies directed to the surface of HEp3 cells were obtained by subtractive im-
munization (Zijlstra et al., 2003; Testa et al., 1999) and purified endotoxin free
by protein-G sepharose affinity purification. To generate cell lines expressing
green fluorescent protein (GFP), cultured cells were infected with PLXN-GFP
and selected by neomycin selection without clonal propagation. Selected cells
were passaged in vivo to maintain the metastatic phenotype.
The Chick Embryo Metastasis Model
The quantitative spontaneous and experimental metastasis assays were per-
formed as described previously (Zijlstra et al., 2002). In spontaneous metasta-
sis assays, the tumor cells are placed directly on the CAM where a primary tu-
mor forms over a period of 7 days, while in experimental metastasis, the tumor
cells are injected i.v. and allowed to colonize organs for 7 days. At the end of
indicated time periods, tumors are harvested, weighed, and processed for his-
tology. Metastasis is determined by harvesting lower CAM (LCAM), lung, and
liver and processing the tissue for the detection of human DNA by alu PCR. For
i.v. delivery of antibodies, the injections were performed the day after tumor
cell application unless indicated otherwise. To analyze arrest, extravasation,
growth, and colonization, 5 3 104 cells were injected i.v. into each egg at de-
velopmental day 12. Human tumor cell metastasis in the ex ovomodel was de-
veloped on the basis of our previously established CAM angiogenesis model
(Seandel et al., 2001; Lewis et al., 2006). Human tumor cell behavior was an-
alyzed in shell-less embryos as described below after i.v. injection using a glass
capillary needle or during primary tumor formation after topical application of
tumor cells directly onto the CAM.
Mouse SCID Spontaneous Metastasis
To assess the metastasis of HEp3 cells in mice, 3 3 106 cells were injected
subcutaneously and tumors were allowed to form for 17 days. Control mAb
or mAb 1A5 was administered i.v. at 5 days and 13 days after tumor cell injec-
tion. The lungs of tumor-bearing animals were harvested at the end of the ex-
periment, and 50mg of lung tissuewas processed as described for chick lungs
(Zijlstra et al., 2002). All animals (mice and chick embryos) were housed, main-
tained, and treated by procedures approved by our Institutional Animal Core
and Use Committee (IACUC) and state and federal guidelines for the humane
treatment of laboratory animals.
Detection of Human Tumor Cell Arrest, Growth, Intravasation,
and Metastasis
The detection of human tumor cell metastasis in chick tissue was based upon
the quantitative detection of human alu sequences present in chick tissue DNA
extracts (Zijlstra et al., 2002). To approximate the actual number of tumor cells
present in each tissue sample the alu signal from experimental samples was
interpolated with a standard curve. A separate standard curve was generated
for mice and chicken. The actual number of tumor cells/50 mg lung tissue
could be determined over a range of 50 to 100,000 cells/50 mg tissue. Tumor
cell arrestwas determined by quantifying the number of cells present in a tissue
within 24 hr after i.v. injection. In vivo tumor cell growth was quantified by de-
termining the expansion of arrested cells from day 1 to day 4. Intravasationwas
determined by comparing the number of cells that appeared in lung, liver, or
lower CAM of tumor-bearing animals on day 5 versus day 6. The increase in
cell number that could not be accounted for by growth of the cells present
on day 5 is considered the number of intravasated cells.
Human Tumor Cell Motility
In Vitro Migration Assays
Cellular migration in vitro was analyzed using a Boyden chamber system as
previously described (Degryse et al., 1999). Pore filters (8 mm) were coated
with indicated matrix components, and matrix-mediated migration was ana-
lyzed 16 hr after 50,000 cells were applied to the top chamber. Antibodies
were applied at 10 mg/ml unless stated otherwise. Migrating cells were quan-
tified in ten random fields of three replicate wells.
End Point In Vivo Extravasation and Motility Assays
The ability of tumor cells to extravasate was analyzed during experimental me-
tastasis by imaging the location of GFP-expressing tumor cells with respect to
the vasculature by which they arrived. To achieve this, 1 3 105 GFP-express-
ing HEp3 and HT1080 cells were i.v. injected and allowed to arrest and colo-
nize the CAM for 24 hr to 5 days at which time the CAM was harvested andCancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc. 231
(1999). Src-dependence and pertussis-toxin sensitivity of urokinase
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ately prior to harvesting, 50 mg of Rhodamine-conjugated Lens Culinaris
Agglutinin (LCA) (Vector Laboratories Inc., Burlingame CA) was injected i.v.
to label the chick vasculature (Jilani et al., 2003). Tumor cells were considered
to have extravasatedwhen theGFP signal was no longer inside the Rhodamine
labeled vasculature, as determined by confocal imaging (MRC1024 laser
scanning confocal microscope) (Biorad, Hercules CA).
Themotility of human tumor cells during experimental metastasis in vivowas
assessed by imaging tumor cells in the CAM after i.v. injection. 1 3 105 GFP-
expressing tumor cells were injected i.v. on embryonic day 12 and colonization
of the CAM as well as tumor cell dissemination within the CAM stroma was
assessed by harvesting CAM from 3 animals at indicated time points and
imaging the tumor cell population by epifluorescent microscopy (Olympus
BX60, Melville, NY). Digital images were acquired using the C-view imaging
software (DVC, Austin, TX) and further processed using Photoshop (Adobe,
San Jose, CA).
As the arrested tumor cell population grows, the expanding tumor cell pop-
ulation disseminates throughout the CAM stroma. Failure of the proliferating
tumor cells to migrate results in compact colony formation.
Intravital Real-Time Imaging of Tumor Cell Motility
To achieve real-time imaging of tumor cells migrating within the tissue stroma
and the primary tumor itself, a chick-embryo-imaging unit was constructed.
This unit was designed for the purpose of maintaining the chick embryo under
proper temperature and humidity as well as immobilizing the tissue to be im-
aged while providing a self-contained unit that prevents exposure of themicro-
scope electronics and objectives to humidity and heat. This chick-embryo-im-
aging unit was built around the shell-less (ex ovo) system developed previously
(Seandel et al., 2001) in which chick embryos are maintained without the shell
in a plastic dish. The CAM, which is normally located immediately underneath
the eggshell in ovo, is now exposed as a free-floating organ atop the develop-
ing embryo. Migration of cells within the primary tumor was monitored by im-
aging a tumor generated within the CAM underneath a coverslip. This was
achieved by implanting a mixture of GFP-expressing and non-GFP tumor cells
directly into the CAM mesenchyme using a capillary needle at developmental
day 10 and covering the area with a sterile coverslip. The animal was subse-
quently returned to the incubator and imaged at predetermined time points
by immobilizing the coverslip in the chick-embryo-imaging unit.
Image Capture and Processing
Real-time imaging of tumor cell migration was achieved by capturing a four-di-
mensional image series of the entire tumor within the CAM. A 150 mm image
stack was captured with a 15 mm step size every 15 min for 12.5 hr (50 frames)
using an upright epifluorescent microscope with a motorized Z stage (Carl
Zeiss, Thornwood, NY) controlled by Openlab (Improvision, Lexington, MA).
For each time point, a 60 mm stack containing the in focus images of the tumor
was selected and projected as an ‘‘extended focus’’ image using Volocity (Im-
provision, Lexington, MA). Image drift and rotation was correct by using the
Stack_Reg plugin (Biomedical Imaging Group, http://bigwww.epfl.ch/) running
in the open-source software ImageJ (NIH). Cell tracking and motility quantita-
tion was completed by visually determining the centroid (center of the cell
body) at every 15 min interval and tracing it from one frame to the next using
the Manual_Tracking plugin running in ImageJ. These traces were used for mi-
gration analysis of the motion parameters velocity, turn angle, and persistence
asdescribedpreviously (Mandeville et al., 1995). Totalmigrationwasdefinedas
the total distance migrated, while productive migration was defined as the ab-
solute distance from the point of origin. The ability of a cell tomobilize itself (mo-
tility) is defined as centroid movement in excess of one body length (>20 mm).
Histological Analysis of Chick Tissues
For fluorescent staining, each tissue was frozen in Tissue-Tec mounting me-
dia, and 6 mm sections were fixed in Zinc-Formalin and processed for immu-
nological detection of tumor antigens. To detect antigen expression, tumor tis-
sue was incubated with tumor-specific mouse monoclonal antibodies, and
primary antibody binding was visualized with fluorescently labeled secondary
(anti-mouse) antibody. To visualize in vivo tumor localization of tumor specific
antibodies, tumor tissue and control tissues from antibody-injected animals
were incubated with fluorescently labeled secondary anti-mouse antibodies
only.232 Cancer Cell 13, 221–234, March 2008 ª2008 Elsevier Inc.SUPPLEMENTAL DATA
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